Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GNLX 
Genelux Corporation Common Stock (GNLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: GNLX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.33
1 Year Target Price $19.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.96% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.01M USD | Price to earnings Ratio - | 1Y Target Price 19.33 |
Price to earnings Ratio - | 1Y Target Price 19.33 | ||
Volume (30-day avg) 5 | Beta 0.05 | 52 Weeks Range 1.99 - 8.54 | Updated Date 12/17/2025 |
52 Weeks Range 1.99 - 8.54 | Updated Date 12/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -64.27% | Return on Equity (TTM) -123.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 138101778 | Price to Sales(TTM) 12362.41 |
Enterprise Value 138101778 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 38051771 | Shares Floating 29367586 |
Shares Outstanding 38051771 | Shares Floating 29367586 | ||
Percent Insiders 13.05 | Percent Institutions 30.7 |
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.